Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

65.70USD
25 Jun 2019
Change (% chg)

$-12.75 (-16.25%)
Prev Close
$78.45
Open
$70.50
Day's High
$70.67
Day's Low
$65.06
Volume
10,859,099
Avg. Vol
1,690,332
52-wk High
$100.23
52-wk Low
$65.06

Select another date:
Photo

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

June 25 Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection.

Deals of the day-Mergers and acquisitions

June 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

US STOCKS-Wall St sinks on trade jitters ahead of Powell speech

* Indexes down: 0.15%, S&P 0.32%, Nasdaq 0.61% (Updates to mid-day, changes dateline, byline)

US STOCKS-Wall St dragged down by Iran tensions, trade worries; Fed in focus

* Indexes down: 0.21%, S&P 0.41%, Nasdaq 0.75% (Changes comment, adds details, updates prices)

AbbVie nears deal to buy Allergan for more than $60 bln - WSJ

June 25 AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than $60 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

AbbVie halts enrollment after brain cancer trial misses goal, shares fall

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

AbbVie halts enrollment after brain cancer trial misses goal, shares fall

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

UPDATE 1-AbbVie halts enrollment after brain cancer trial misses goal, shares fall

May 17 AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

Select another date: